Literature DB >> 9384296

Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis.

T S Steiner1, C A Flores, T T Pizarro, R L Guerrant.   

Abstract

Twenty-two patients with Clostridium difficile colitis as determined by positive enzyme immunoassay for toxin A were evaluated for fecal inflammatory markers and their relationship to the severity of illness. Fourteen of 22 specimens were positive for fecal lactoferrin (FLF), with titers from 1:50 to 1:800. Nine of 10 stools tested had ratios of interleukin-1beta (IL-1beta) to IL-1 receptor antagonist (IL-1ra) of >0.01. Seventeen of 22 specimens also had elevated IL-8 concentrations, and 12 of 14 had elevated IL-1beta concentrations. A review of the 18 available patient records revealed that fecal IL-8 concentrations, IL-1beta/IL-1ra ratios, and FLF titers were significantly higher in patients with moderate to severe disease than in patients with mild disease. These findings suggest that the proinflammatory effects of C. difficile may directly influence clinical characteristics of human disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9384296      PMCID: PMC170647          DOI: 10.1128/cdli.4.6.719-722.1997

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  23 in total

1.  Role of stool screening tests in diagnosis of inflammatory bacterial enteritis and in selection of specimens likely to yield invasive enteric pathogens.

Authors:  R P Silletti; G Lee; E Ailey
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

Review 2.  Diarrhoeal disease: current concepts and future challenges. Intestinal cytokines in inflammatory bowel disease and invasive diarrhoea.

Authors:  T T MacDonald; S H Murch; S W Nicholls; E J Breese
Journal:  Trans R Soc Trop Med Hyg       Date:  1993-12       Impact factor: 2.184

3.  Persistence of local cytokine production in shigellosis in acute and convalescent stages.

Authors:  R Raqib; A A Lindberg; B Wretlind; P K Bardhan; U Andersson; J Andersson
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

4.  Fecal leukocytes in stool specimens submitted for Clostridium difficile toxin assay.

Authors:  C E Marx; A Morris; M L Wilson; L B Reller
Journal:  Diagn Microbiol Infect Dis       Date:  1993 May-Jun       Impact factor: 2.803

5.  CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin.

Authors:  C Pothoulakis; I Castagliuolo; J T LaMont; A Jaffer; J C O'Keane; R M Snider; S E Leeman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

6.  Comparison of fecal lactoferrin latex agglutination assay and methylene blue microscopy for detection of fecal leukocytes in Clostridium difficile-associated disease.

Authors:  W H Yong; A R Mattia; M J Ferraro
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

7.  Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.

Authors:  D G Teasley; D N Gerding; M M Olson; L R Peterson; R L Gebhard; M J Schwartz; J T Lee
Journal:  Lancet       Date:  1983-11-05       Impact factor: 79.321

8.  Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea.

Authors:  A Anand; B Bashey; T Mir; A E Glatt
Journal:  Am J Gastroenterol       Date:  1994-04       Impact factor: 10.864

9.  Cytokine secretion in acute shigellosis is correlated to disease activity and directed more to stool than to plasma.

Authors:  R Raqib; B Wretlind; J Andersson; A A Lindberg
Journal:  J Infect Dis       Date:  1995-02       Impact factor: 5.226

10.  Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit.

Authors:  C P Kelly; S Becker; J K Linevsky; M A Joshi; J C O'Keane; B F Dickey; J T LaMont; C Pothoulakis
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

View more
  46 in total

Review 1.  Clostridium difficile testing: after 20 years, still challenging.

Authors:  Tracy D Wilkins; David M Lyerly
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

Review 2.  Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?

Authors:  David Brown
Journal:  Nat Rev Drug Discov       Date:  2015-10-23       Impact factor: 84.694

Review 3.  Considering the Immune System during Fecal Microbiota Transplantation for Clostridioides difficile Infection.

Authors:  Alyse L Frisbee; William A Petri
Journal:  Trends Mol Med       Date:  2020-02-17       Impact factor: 11.951

4.  Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain.

Authors:  S W Pawlowski; G Calabrese; G L Kolling; J Platts-Mills; R Freire; C AlcantaraWarren; B Liu; R B Sartor; R L Guerrant
Journal:  J Infect Dis       Date:  2010-10-26       Impact factor: 5.226

5.  Recurrent Clostridium difficile Infection in Children: Patient Risk Factors and Markers of Intestinal Inflammation.

Authors:  Maribeth R Nicholson; Jonathan D Crews; Jeffrey R Starke; Zhi-Dong Jiang; Herbert DuPont; Kathryn Edwards
Journal:  Pediatr Infect Dis J       Date:  2017-04       Impact factor: 2.129

6.  Loss of Interleukin-10 (IL-10) Signaling Promotes IL-22-Dependent Host Defenses against Acute Clostridioides difficile Infection.

Authors:  Emily S Cribas; Joshua E Denny; Jeffrey R Maslanka; Michael C Abt
Journal:  Infect Immun       Date:  2021-04-16       Impact factor: 3.441

7.  Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection.

Authors:  Rana E El Feghaly; Jennifer L Stauber; Elena Deych; Carlos Gonzalez; Phillip I Tarr; David B Haslam
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

Review 8.  Environmental Enteric Dysfunction in Children.

Authors:  Sana Syed; Asad Ali; Christopher Duggan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-07       Impact factor: 2.839

9.  Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure.

Authors:  Simon A Hirota; Vadim Iablokov; Sarah E Tulk; L Patrick Schenck; Helen Becker; Jimmie Nguyen; Samir Al Bashir; Tanis C Dingle; Austin Laing; Jianrui Liu; Yan Li; Jeff Bolstad; George L Mulvey; Glen D Armstrong; Wallace K MacNaughton; Daniel A Muruve; Justin A MacDonald; Paul L Beck
Journal:  Infect Immun       Date:  2012-10-08       Impact factor: 3.441

10.  Elevated levels of intestinal inflammation in Clostridium difficile infection associated with fluoroquinolone-resistant C. difficile.

Authors:  S W Pawlowski; L Archbald-Pannone; R J Carman; C Alcantara-Warren; D Lyerly; C W Genheimer; D N Gerding; R L Guerrant
Journal:  J Hosp Infect       Date:  2009-08-26       Impact factor: 3.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.